Marc Gleeson
Amministratore Delegato presso Azura Ophthalmics Pty Ltd.
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Yair Alster | M | - |
Azura Ophthalmics Pty Ltd.
 Azura Ophthalmics Pty Ltd. Medical SpecialtiesHealth Technology Azura Ophthalmics Ltd. develops therapies for meibomian gland dysfunction. It offers a portfolio of compounds in combination with a novel drug delivery platform to advance a portfolio of treatments for meibomian gland dysfunction. The company was founded by Yair Alster in 1980 and is headquartered in Tel Aviv, Israel. | 44 anni |
| Yehuda Ivri | M | 72 |
Kedalion Therapeutics, Inc.
 Kedalion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kedalion Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of topical ophthalmology therapies based on its proprietary AcuStream platform. The company was founded by Mark Blumenkranz and Ehud Ivri and is headquartered in Menlo Park, CA. | - |
| Darius Kharabi | M | 45 |
Kedalion Therapeutics, Inc.
Kedalion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kedalion Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of topical ophthalmology therapies based on its proprietary AcuStream platform. The company was founded by Mark Blumenkranz and Ehud Ivri and is headquartered in Menlo Park, CA. | - |
| John S. Power | M | - |
Kedalion Therapeutics, Inc.
Kedalion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kedalion Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of topical ophthalmology therapies based on its proprietary AcuStream platform. The company was founded by Mark Blumenkranz and Ehud Ivri and is headquartered in Menlo Park, CA. | - |
| Heather Elizabeth Preston | M | 58 |
Azura Ophthalmics Pty Ltd.
Azura Ophthalmics Pty Ltd. Medical SpecialtiesHealth Technology Azura Ophthalmics Ltd. develops therapies for meibomian gland dysfunction. It offers a portfolio of compounds in combination with a novel drug delivery platform to advance a portfolio of treatments for meibomian gland dysfunction. The company was founded by Yair Alster in 1980 and is headquartered in Tel Aviv, Israel. | - |
| Steven Altschuler | M | 70 |
Azura Ophthalmics Pty Ltd.
Azura Ophthalmics Pty Ltd. Medical SpecialtiesHealth Technology Azura Ophthalmics Ltd. develops therapies for meibomian gland dysfunction. It offers a portfolio of compounds in combination with a novel drug delivery platform to advance a portfolio of treatments for meibomian gland dysfunction. The company was founded by Yair Alster in 1980 and is headquartered in Tel Aviv, Israel. | 3 anni |
| Dana Mead | M | 64 |
Kedalion Therapeutics, Inc.
Kedalion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kedalion Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of topical ophthalmology therapies based on its proprietary AcuStream platform. The company was founded by Mark Blumenkranz and Ehud Ivri and is headquartered in Menlo Park, CA. | - |
| Anat Naschitz | F | 56 |
Azura Ophthalmics Pty Ltd.
Azura Ophthalmics Pty Ltd. Medical SpecialtiesHealth Technology Azura Ophthalmics Ltd. develops therapies for meibomian gland dysfunction. It offers a portfolio of compounds in combination with a novel drug delivery platform to advance a portfolio of treatments for meibomian gland dysfunction. The company was founded by Yair Alster in 1980 and is headquartered in Tel Aviv, Israel. | - |
| Chris Nave | M | 49 |
Azura Ophthalmics Pty Ltd.
Azura Ophthalmics Pty Ltd. Medical SpecialtiesHealth Technology Azura Ophthalmics Ltd. develops therapies for meibomian gland dysfunction. It offers a portfolio of compounds in combination with a novel drug delivery platform to advance a portfolio of treatments for meibomian gland dysfunction. The company was founded by Yair Alster in 1980 and is headquartered in Tel Aviv, Israel. | - |
| Casey Dougan | M | - |
Kedalion Therapeutics, Inc.
Kedalion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kedalion Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of topical ophthalmology therapies based on its proprietary AcuStream platform. The company was founded by Mark Blumenkranz and Ehud Ivri and is headquartered in Menlo Park, CA. | 5 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Mark Blumenkranz | M | 73 |
Kedalion Therapeutics, Inc.
Kedalion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kedalion Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of topical ophthalmology therapies based on its proprietary AcuStream platform. The company was founded by Mark Blumenkranz and Ehud Ivri and is headquartered in Menlo Park, CA. | 3 anni |
| Peter D. Noymer | M | 57 |
Kedalion Therapeutics, Inc.
Kedalion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kedalion Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of topical ophthalmology therapies based on its proprietary AcuStream platform. The company was founded by Mark Blumenkranz and Ehud Ivri and is headquartered in Menlo Park, CA. | - |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 7 | 58.33% |
| Israele | 5 | 41.67% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Marc Gleeson
- Contatti personali
